HN1999000075A - Agonistas y antagonistas il-2 selectivos - Google Patents
Agonistas y antagonistas il-2 selectivosInfo
- Publication number
- HN1999000075A HN1999000075A HN1999000075A HN1999000075A HN1999000075A HN 1999000075 A HN1999000075 A HN 1999000075A HN 1999000075 A HN1999000075 A HN 1999000075A HN 1999000075 A HN1999000075 A HN 1999000075A HN 1999000075 A HN1999000075 A HN 1999000075A
- Authority
- HN
- Honduras
- Prior art keywords
- selective
- agonists
- antagonists
- present
- natural killer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE EN TERMINOS GENERALES A LOS CAMPOS DE LA FARMACOLOGIA E INMUNOLOGIA. MAS ESPECIFICAMENTE, A NOVEDOSAS COMPOSICIONES DE MATERIAL PARA LA ACTIVACION SELECTIVA DE CELULAS T (PHABLASTOS), Y QUE PRESENTAN UNA ACTIVACION REDUCIDA DE LAS CELULAS ASESINAS NATURALES (NK, NATURAL KILLER CELLS).LAS NOVEDOSAS COMPOSICIONES INCLUYEN VARIANTES DE LA FAMILIA DE LAS CITOQUINAS Y EN PARTICULAR LA INTERLEUQUINA-2 HUMANA ("IL-2 SELECTIVOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8008098A | 1998-05-15 | 1998-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
HN1999000075A true HN1999000075A (es) | 1999-09-29 |
Family
ID=22155135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HN1999000075A HN1999000075A (es) | 1998-05-15 | 1999-05-14 | Agonistas y antagonistas il-2 selectivos |
Country Status (39)
Country | Link |
---|---|
EP (1) | EP1076704B1 (es) |
JP (1) | JP4276783B2 (es) |
KR (1) | KR100607609B1 (es) |
CN (2) | CN100366742C (es) |
AR (1) | AR020322A1 (es) |
AT (1) | ATE351907T1 (es) |
AU (1) | AU759697B2 (es) |
BG (1) | BG65139B1 (es) |
BR (1) | BRPI9910504B1 (es) |
CA (1) | CA2327349C (es) |
CO (1) | CO5070701A1 (es) |
CU (2) | CU23273B7 (es) |
CY (1) | CY1107533T1 (es) |
CZ (1) | CZ302071B6 (es) |
DE (1) | DE69934881T2 (es) |
DK (1) | DK1076704T3 (es) |
DZ (1) | DZ2788A1 (es) |
ES (1) | ES2281175T3 (es) |
HK (1) | HK1039963B (es) |
HN (1) | HN1999000075A (es) |
HU (1) | HU226142B1 (es) |
IL (2) | IL139136A0 (es) |
MY (1) | MY130274A (es) |
NO (1) | NO329235B1 (es) |
NZ (1) | NZ508098A (es) |
PA (1) | PA8472601A1 (es) |
PE (1) | PE20000475A1 (es) |
PL (1) | PL201675B1 (es) |
PT (1) | PT1076704E (es) |
RO (1) | RO122150B1 (es) |
RU (1) | RU2235729C2 (es) |
SI (1) | SI20643B (es) |
SK (1) | SK288100B6 (es) |
SV (1) | SV1999000061A (es) |
TN (1) | TNSN99090A1 (es) |
TR (1) | TR200003354T2 (es) |
TW (1) | TWI223663B (es) |
UA (1) | UA73719C2 (es) |
WO (1) | WO1999060128A1 (es) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000058456A2 (en) * | 1999-03-30 | 2000-10-05 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinacious compounds |
EP1935431A3 (en) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Cancer treatments by using a combination of an antibody against her2 and interleukin-2 |
US6689353B1 (en) * | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
MY139948A (en) * | 2000-09-28 | 2009-11-30 | Bayer Corp | Enhanced transfection system |
US7723102B2 (en) * | 2000-09-28 | 2010-05-25 | Bayer Corporation | Enhanced transfection system |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
MXPA04005266A (es) * | 2001-12-04 | 2004-10-11 | Merck Patent Gmbh | Inmunocitocinas con selectividad modulada. |
WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
CA2531773A1 (en) * | 2003-07-21 | 2005-02-17 | Transgene S.A. | Novel multifunctional cytokines |
DE602004031341D1 (de) | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
JP4746552B2 (ja) | 2003-11-04 | 2011-08-10 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗cd40抗体の使用 |
US7858081B2 (en) * | 2004-02-27 | 2010-12-28 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | IL-15 mutants having agonists/antagonists activity |
KR20070003934A (ko) * | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
WO2009061853A2 (en) * | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
CN101244261B (zh) * | 2008-03-10 | 2010-09-15 | 山东大学 | 一种含未复性重组蛋白的生物制剂及其制备方法与应用 |
DE102008023820A1 (de) * | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
JP5766124B2 (ja) | 2009-01-21 | 2015-08-19 | アムジェン インコーポレイテッド | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
CN102101885B (zh) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
AU2011325990C1 (en) | 2010-11-12 | 2017-06-08 | Nektar Therapeutics | Conjugates of an IL-2 moiety and a polymer |
EP2655409A4 (en) | 2010-12-22 | 2015-07-01 | Univ Leland Stanford Junior | SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 |
PL3489255T3 (pl) | 2011-02-10 | 2021-11-22 | Roche Glycart Ag | Zmutowane polipeptydy interleukiny-2 |
WO2012119093A1 (en) * | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
EP3049445A4 (en) | 2013-09-24 | 2017-10-25 | Medicenna Therapeutics, Inc. | Interleukin-2 fusion proteins and uses thereof |
JP6306201B2 (ja) | 2014-02-06 | 2018-04-04 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | インターロイキン−2融合タンパク質及びその使用 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
JP6592505B2 (ja) | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
CN113234138A (zh) * | 2014-08-11 | 2021-08-10 | 德里尼亚公司 | 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体 |
US20170204154A1 (en) * | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
CN109689694B (zh) * | 2016-05-19 | 2022-11-22 | 通用医疗公司 | 与其受体IL-2Rβ结合的IL2作为用来增强自然杀伤细胞和调节性T细胞活性的平台 |
CA3026477A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
WO2017220704A1 (en) | 2016-06-22 | 2017-12-28 | David Klatzmann | Genetically modified t lymphocytes |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
SG11201903882VA (en) | 2016-11-08 | 2019-05-30 | Delinia Inc | Il-2 variants for the treatment of autoimmune diseases |
RU2769871C2 (ru) * | 2016-12-13 | 2022-04-07 | Делиниа, Инк. | Поливалентные модуляторы регуляторных t-клеток |
EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
JOP20190271A1 (ar) * | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
CN111107868A (zh) * | 2017-05-24 | 2020-05-05 | 诺华股份有限公司 | 抗体细胞因子移植蛋白及使用方法 |
JP2020520665A (ja) | 2017-05-24 | 2020-07-16 | ノバルティス アーゲー | 抗体−サイトカイングラフト化タンパク質及び癌の治療における使用方法 |
KR20200010354A (ko) | 2017-05-24 | 2020-01-30 | 팬디온 테라퓨틱스, 인코포레이티드 | 표적화된 면역관용 |
CA3067909A1 (en) | 2017-06-19 | 2018-12-27 | Medicenna Therapeutics Inc. | Uses and methods for il-2 superagonists, agonists, and fusions thereof |
MX2020001336A (es) * | 2017-08-03 | 2020-08-20 | Synthorx Inc | Conjugados de citoquina para el tratamiento de enfermedades autoinmunes. |
WO2019104092A1 (en) * | 2017-11-21 | 2019-05-31 | The Board Of Trustees Of The Leland Stanford Junior University | Partial agonists of interleukin-2 |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
MA51291A (fr) | 2017-12-19 | 2020-10-28 | Xencor Inc | Protéines de fusion il-2 fc modifiées |
WO2019158764A1 (en) | 2018-02-16 | 2019-08-22 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
TW202003551A (zh) | 2018-03-28 | 2020-01-16 | 美商必治妥美雅史谷比公司 | 介白素-2/介白素-2受體阿法融合蛋白及其使用方法 |
BR112020019639A2 (pt) | 2018-03-28 | 2021-01-05 | Ascendis Pharma Oncology Division A/S | Conjugados de il-2 |
WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
EP3827014A1 (en) * | 2018-07-24 | 2021-06-02 | BioNTech RNA Pharmaceuticals GmbH | Il2 agonists |
WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
KR102201086B1 (ko) * | 2018-09-17 | 2021-01-11 | (주)지아이이노베이션 | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도 |
CN113383013B (zh) | 2018-12-21 | 2022-11-04 | 江苏恒瑞医药股份有限公司 | 一种人白细胞介素2变体或其衍生物 |
KR20220035333A (ko) | 2019-05-20 | 2022-03-22 | 팬디온 오퍼레이션스, 인코포레이티드 | Madcam 표적 면역관용 |
TW202115105A (zh) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Rna製藥有限公司 | Il2激動劑 |
WO2021030602A1 (en) * | 2019-08-13 | 2021-02-18 | Amgen Inc. | Interleukin-2 muteins for the expansion of t-regulatory cells |
KR20220139293A (ko) | 2019-12-12 | 2022-10-14 | 일투 파마 | 인터류킨 2 키메라 구축물 |
US20230040604A1 (en) | 2019-12-17 | 2023-02-09 | Amgen Inc. | Interleukin-2 in combination with tnf receptor family members for the expansion of t-regulatory cells |
US11633488B2 (en) | 2020-01-10 | 2023-04-25 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
KR20240046306A (ko) | 2020-01-14 | 2024-04-08 | 신테카인, 인크. | 편향된 il2 뮤테인 방법 및 조성물 |
WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
EP4122952A4 (en) | 2020-03-19 | 2024-05-29 | Innovent Biologics (Singapore) Pte. Ltd. | INTERLEUKIN-2 MUTANT AND ITS USE |
TW202204387A (zh) * | 2020-03-31 | 2022-02-01 | 南韓商韓美藥品股份有限公司 | 新穎免疫刺激il-2類似物 |
MX2022014082A (es) | 2020-06-03 | 2022-12-07 | Ascendis Pharma Oncology Div A/S | Secuencias de interleucina (il-2) y usos de las mismas. |
CN114507643A (zh) * | 2020-10-29 | 2022-05-17 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-2的多能干细胞衍生物及应用 |
EP4236962A1 (en) | 2020-10-29 | 2023-09-06 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
CN113308477A (zh) * | 2021-04-08 | 2021-08-27 | 华南农业大学 | 一种鸭il-2基因真核表达重组质粒及其制备方法 |
KR20240082364A (ko) | 2021-09-22 | 2024-06-10 | 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 | 인터루킨-2 돌연변이 및 이의 융합 단백질 |
WO2023057588A1 (en) | 2021-10-06 | 2023-04-13 | Iltoo Pharma | Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues |
CN114875069B (zh) * | 2022-04-22 | 2023-09-15 | 四川大学 | 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途 |
US20240076343A1 (en) * | 2022-06-16 | 2024-03-07 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
WO2024056154A1 (en) | 2022-09-12 | 2024-03-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin-2 for use in treating autism spectrum disorder |
FR3140287A1 (fr) | 2022-10-03 | 2024-04-05 | Arkema France | Procede de granulation de composes azoiques et granules obtenus |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5696234A (en) * | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
-
1999
- 1999-05-12 DZ DZ990088A patent/DZ2788A1/xx active
- 1999-05-13 PE PE1999000399A patent/PE20000475A1/es not_active Application Discontinuation
- 1999-05-13 SI SI9920034A patent/SI20643B/sl active Search and Examination
- 1999-05-13 IL IL13913699A patent/IL139136A0/xx unknown
- 1999-05-13 AT AT99924232T patent/ATE351907T1/de active
- 1999-05-13 DK DK99924232T patent/DK1076704T3/da active
- 1999-05-13 PA PA19998472601A patent/PA8472601A1/es unknown
- 1999-05-13 CN CNB998086509A patent/CN100366742C/zh not_active Expired - Lifetime
- 1999-05-13 CA CA2327349A patent/CA2327349C/en not_active Expired - Lifetime
- 1999-05-13 AR ARP990102269A patent/AR020322A1/es active IP Right Grant
- 1999-05-13 HU HU0101948A patent/HU226142B1/hu unknown
- 1999-05-13 RU RU2000131593/04A patent/RU2235729C2/ru active
- 1999-05-13 TR TR2000/03354T patent/TR200003354T2/xx unknown
- 1999-05-13 KR KR1020007012747A patent/KR100607609B1/ko not_active IP Right Cessation
- 1999-05-13 PL PL344407A patent/PL201675B1/pl unknown
- 1999-05-13 EP EP99924232A patent/EP1076704B1/en not_active Expired - Lifetime
- 1999-05-13 ES ES99924232T patent/ES2281175T3/es not_active Expired - Lifetime
- 1999-05-13 SK SK1724-2000A patent/SK288100B6/sk not_active IP Right Cessation
- 1999-05-13 UA UA2000127206A patent/UA73719C2/uk unknown
- 1999-05-13 BR BRPI9910504A patent/BRPI9910504B1/pt not_active IP Right Cessation
- 1999-05-13 AU AU40784/99A patent/AU759697B2/en not_active Expired
- 1999-05-13 RO ROA200001123A patent/RO122150B1/ro unknown
- 1999-05-13 NZ NZ508098A patent/NZ508098A/en not_active IP Right Cessation
- 1999-05-13 WO PCT/US1999/010643 patent/WO1999060128A1/en active IP Right Grant
- 1999-05-13 CN CN2007101609093A patent/CN101319247B/zh not_active Expired - Lifetime
- 1999-05-13 TN TNTNSN99090A patent/TNSN99090A1/fr unknown
- 1999-05-13 CZ CZ20004213A patent/CZ302071B6/cs not_active IP Right Cessation
- 1999-05-13 JP JP2000549735A patent/JP4276783B2/ja not_active Expired - Lifetime
- 1999-05-13 PT PT99924232T patent/PT1076704E/pt unknown
- 1999-05-13 DE DE69934881T patent/DE69934881T2/de not_active Expired - Lifetime
- 1999-05-14 TW TW088107812A patent/TWI223663B/zh not_active IP Right Cessation
- 1999-05-14 SV SV1999000061A patent/SV1999000061A/es active IP Right Grant
- 1999-05-14 CO CO99030158A patent/CO5070701A1/es unknown
- 1999-05-14 HN HN1999000075A patent/HN1999000075A/es unknown
- 1999-05-14 MY MYPI99001912A patent/MY130274A/en unknown
-
2000
- 2000-10-18 IL IL139136A patent/IL139136A/en not_active IP Right Cessation
- 2000-11-08 BG BG104929A patent/BG65139B1/bg unknown
- 2000-11-14 NO NO20005762A patent/NO329235B1/no not_active IP Right Cessation
- 2000-11-15 CU CU20000257A patent/CU23273B7/es not_active IP Right Cessation
-
2002
- 2002-02-21 HK HK02101283.2A patent/HK1039963B/zh not_active IP Right Cessation
- 2002-06-19 CU CU20020125A patent/CU23272A1/es not_active IP Right Cessation
-
2007
- 2007-03-09 CY CY20071100330T patent/CY1107533T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HN1999000075A (es) | Agonistas y antagonistas il-2 selectivos | |
ES2194992T3 (es) | Procedimientos para la incorporacion estable de sustancias en matrices vitreas secas esponjosas, y composiciones asi obtenidas. | |
GT199700015A (es) | Inhibidores de metaloproteinasa, composiciones farmaceuticas que las contienen y su uso farmaceutico y metodosyeficazproducto intermedio para su preparacion. | |
MX9302944A (es) | Compuestos en n-yodopropargil-hidantoina, sus composiciones y su preparacion y empleo como agentes antimicrobianos. | |
AR033717A1 (es) | Composicion pesticida que comprende compuestos de malononitrilo | |
DK1265645T3 (da) | Fast parfumeret formulering i form af mikrokugler og anvendelse deraf | |
BR9912975A (pt) | Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso | |
PT1093819E (pt) | Compostos e composicoes para fornecimento de agentes activos | |
DK1257176T3 (da) | Anvendelse af syrestabile proteaser i dyrefoder | |
ES2183407T3 (es) | Composicion polimera de mecha para un producto de vela ambientadora. | |
ES2033235T3 (es) | N-n' -diacilhidrazinas n'-sustituidas para insecticidas. | |
AR021596A1 (es) | Compuestos que inhiben la procolageno c-proteinasa. | |
ES2165723T3 (es) | Composiciones farmaceuticas conteniendo mupirocina. | |
CO5221025A1 (es) | 4-trifluorometil-3-oxazolilpiridinas, procedimiento para su preparacion, agentes que las contienen y su uso como agente para la lucha contra organismos daninos | |
ES2184398T3 (es) | Mezclas herbicidas a base de aclonifeno y de clomazona. | |
BR0011174A (pt) | Composições, compostos, compostos isolados e métodos para controlar pestes | |
AR001813A1 (es) | Derivados de cromona procedimiento para prepararlos y las composiciones farmacéutica que los contienen | |
ES2153503T3 (es) | Nuevas composiciones herbicidas sinergicas que comprenden compuestos de 4-benzoilisoxazoles y 2,6-dinitroanilinas. | |
ES2193297T3 (es) | Agentes que previenen el mal olor humano. | |
AR030853A1 (es) | Composicion plaguicida | |
PT952975E (pt) | Compostos bi-aromaticos ligados por um radical hetero-etinileno e composicoes farmaceuticas e cosmeticas que os contem | |
GT199400055A (es) | Metodo para la preparacion de 3-(heterociclilo biciclicos)-6-fluoroalquiluracilos | |
MY117511A (en) | Pesticide formulations containing alkoxylated amine neutralized aromaticsulfonic acid surfactants. | |
AR004484A1 (es) | Nuevas 1,2,3,4-tetrahidro-2-naftalenaminas fenilo-sustituidas en el anillo aromatico, su preparacion, sus aplicaciones terapeuticas y las composicionesfarmaceuticas que las contienen. | |
ES2170922T3 (es) | Composicion farmaceutica a base de matrices lipofilas estabilizadas para la liberacion controlada de principios activos. |